Market Closed -
Swiss Exchange
11:31:03 2024-05-29 EDT
|
5-day change
|
1st Jan Change
|
31.57
CHF
|
-2.23%
|
|
-1.59%
|
+16.67%
|
Fiscal Period: December |
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
13,854
|
14,860
|
-
|
-
|
Enterprise Value (EV)
1 |
16,969
|
17,975
|
17,591
|
16,822
|
P/E ratio
|
179
x
|
20.7
x
|
15.2
x
|
11.7
x
|
Yield
|
1.4%
|
1.81%
|
2.37%
|
3.02%
|
Capitalization / Revenue
|
1.44
x
|
1.44
x
|
1.36
x
|
1.29
x
|
EV / Revenue
|
1.76
x
|
1.75
x
|
1.61
x
|
1.45
x
|
EV / EBITDA
|
9.74
x
|
8.88
x
|
7.61
x
|
6.42
x
|
EV / FCF
|
-72.5
x
|
34.8
x
|
17.2
x
|
13.6
x
|
FCF Yield
|
-1.38%
|
2.87%
|
5.8%
|
7.33%
|
Price to Book
|
1.6
x
|
1.61
x
|
1.5
x
|
1.38
x
|
Nbr of stocks (in thousands)
|
431,000
|
429,717
|
-
|
-
|
Reference price
2 |
32.14
|
34.58
|
34.58
|
34.58
|
Announcement Date
|
3/13/24
|
-
|
-
|
-
|
Fiscal Period: December |
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
9,647
|
10,292
|
10,956
|
11,564
|
EBITDA
1 |
-
|
1,743
|
2,025
|
2,312
|
2,622
|
EBIT
1 |
-
|
1,488
|
1,761
|
2,044
|
2,346
|
Operating Margin
|
-
|
15.42%
|
17.11%
|
18.66%
|
20.29%
|
Earnings before Tax (EBT)
1 |
1,102
|
130
|
959.1
|
1,362
|
1,748
|
Net income
1 |
848
|
77
|
731.3
|
973.6
|
1,252
|
Net margin
|
-
|
0.8%
|
7.11%
|
8.89%
|
10.82%
|
EPS
2 |
-
|
0.1800
|
1.672
|
2.274
|
2.950
|
Free Cash Flow
1 |
-
|
-234
|
516.4
|
1,020
|
1,233
|
FCF margin
|
-
|
-2.43%
|
5.02%
|
9.31%
|
10.66%
|
FCF Conversion (EBITDA)
|
-
|
-
|
25.5%
|
44.12%
|
47.04%
|
FCF Conversion (Net income)
|
-
|
-
|
70.61%
|
104.75%
|
98.53%
|
Dividend per Share
2 |
-
|
0.4500
|
0.6261
|
0.8179
|
1.046
|
Announcement Date
|
8/18/23
|
3/13/24
|
-
|
-
|
-
|
Fiscal Period: December |
2023 S1
|
2023 Q3
|
2023 Q4
|
2023 S2
|
2024 Q1
|
---|
Net sales
1 |
-
|
2,186
|
2,543
|
4,880
|
2,492
|
EBITDA
|
-
|
-
|
-
|
751
|
-
|
EBIT
|
-
|
-
|
-
|
618
|
-
|
Operating Margin
|
-
|
-
|
-
|
12.66%
|
-
|
Earnings before Tax (EBT)
|
362
|
-
|
-
|
-
|
-
|
Net income
|
235
|
-
|
-
|
-
|
-
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
EPS
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
9/5/23
|
10/24/23
|
3/13/24
|
3/13/24
|
5/7/24
|
Fiscal Period: December |
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
3,115
|
3,115
|
2,732
|
1,963
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
1.787
x
|
1.538
x
|
1.182
x
|
0.7486
x
|
Free Cash Flow
1 |
-
|
-234
|
516
|
1,020
|
1,233
|
ROE (net income / shareholders' equity)
|
-
|
11%
|
11.9%
|
13.3%
|
14.4%
|
ROA (Net income/ Total Assets)
|
-
|
5.15%
|
4.63%
|
5.68%
|
6.42%
|
Assets
1 |
-
|
1,494
|
15,778
|
17,128
|
19,495
|
Book Value Per Share
2 |
-
|
20.10
|
21.40
|
23.00
|
25.10
|
Cash Flow per Share
2 |
-
|
0.8400
|
2.680
|
3.160
|
3.790
|
Capex
1 |
-
|
586
|
517
|
484
|
456
|
Capex / Sales
|
-
|
6.07%
|
5.02%
|
4.42%
|
3.94%
|
Announcement Date
|
8/18/23
|
3/13/24
|
-
|
-
|
-
|
Last Close Price
34.58
USD Average target price
39.85
USD Spread / Average Target +15.24% Consensus |
1st Jan change
|
Capi.
|
---|
| +16.67% | 14.86B | | +16.52% | 42.57B | | +18.28% | 21.01B | | +18.15% | 14.47B | | +49.54% | 12.61B | | -0.05% | 6.79B | | -12.56% | 6.57B | | -8.87% | 5.73B | | +14.28% | 5.62B | | +6.11% | 4.66B |
Generic Pharmaceuticals
|